Action of PDE4 inhibitors can prolong or enhance effects of cAMP and... | Download Scientific Diagram
Advances in the Development of Phosphodiesterase-4 Inhibitors | Journal of Medicinal Chemistry
Selective Phosphodiesterase Inhibitors: A New Therapeutic Option in Inflammation and Autoimmunity | Reumatología Clínica
PDE4 subtypes in cancer | Oncogene
PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease: Trends in Pharmacological Sciences
Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders - ScienceDirect
PDE4 inhibitors in COPDFa more selective approach to treatment
Frontiers | Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases
Frontiers | Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
Reducing Neuroinflammation in Psychiatric Disorders: Novel Target of Phosphodiesterase 4 (PDE4) and Developing of the PDE4 Inhibitors | IntechOpen
Phosphodiesterase inhibitor - Wikipedia
PDE4 as Therapeutic Targets in Different Diseases | Encyclopedia MDPI
The effect and associated mechanism of action of phosphodiesterase 4 (PDE4) inhibitor on CD4+ lymphocyte proliferation - Kim - 2021 - Clinical and Experimental Pharmacology and Physiology - Wiley Online Library
Design, synthesis, and biological evaluation of novel catecholopyrimidine based PDE4 inhibitor for the treatment of atopic dermatitis - ScienceDirect
Phosphodiesterase 4 inhibitors | Semantic Scholar
Frontiers | Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease
Phosphodiesterase-4 inhibitor - Wikipedia
DC591017, a phosphodiesterase-4 (PDE4) inhibitor with robust anti-inflammation through regulating PKA-CREB signaling - ScienceDirect
GSK356278 is a Selective and Orally Bioavailable PDE4 Inhibitor - Immune System Research
File:Mechanism of action of PDE4 inhibitor.jpg - Wikimedia Commons
The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition - Guttman‐Yassky - 2019 - Experimental Dermatology - Wiley Online Library
FCPR03 is a Selective Phosphodiesterase 4 (PDE4) Inhibitor - Immune System Research
Inhibition of PDE4B suppresses inflammation by increasing expression of the deubiquitinase CYLD | Nature Communications
R)-(-)-Rolipram, Selective PDE4 inhibitor (CAS 85416-75-7) (ab120031) | Abcam
Inhibition of PDE4 protects neurons against oxygen-glucose deprivation-induced endoplasmic reticulum stress through activation of the Nrf-2/HO-1 pathway - ScienceDirect
